Cardiol Therapeutics (CRDL) Short term Debt (2021 - 2026)

Cardiol Therapeutics has reported Short term Debt for 6 years, with the latest figure at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt changed N/A year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (changed N/A YoY), and the FY2025 full-year result was $1.5 million, changed N/A from the prior year.
• Short term Debt for Q1 2026 stood at $2.7 million, up from $1.5 million in the prior quarter.
• The five-year high for Short term Debt was $3.6 million in Q1 2022, with the low at $2673.4 in Q3 2024.
• Historically, Short term Debt has averaged $1.3 million across 5 years, with a median of $991230.6 in 2024.
• The largest YoY upside for Short term Debt was 493.8% in 2024 against a maximum downside of 99.56% in 2024.
• Cardiol Therapeutics' Short term Debt stood at $309342.3 in 2022, then tumbled by 43.44% to $174948.7 in 2023, then plunged by 98.47% to $2673.4 in 2024, then soared by 57243.04% to $1.5 million in 2025, then soared by 74.44% to $2.7 million in 2026.
• The last three Short term Debt figures came in at $2.7 million (Q1 2026), $1.5 million (Q4 2025), and $2673.4 (Q3 2024), per Business Quant data.